arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Solid Biosciences Inc.

SLDB Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$10.25
Today
as of Sep 4, 16:54 ET
Last 30 days +29.91% Jul 27 → Sep 04
$7.69 $8.42 $9.15 $9.89 $10.62 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$10.20
High
$10.48
Low
$10.20
Volume
$495,296
Avg Vol
$1M
Mkt Cap
$976M
P/E (TTM)
—
Beta
—
52w High
$11.45
52w Low
$3.79
Div Yield
—
Shares Out
$105M

Recent Press Releases & News last 60 days · 3 items

Sep 2 · 12:00 PR GlobeNewswire
Solid Biosciences to Participate at Upcoming Investor Conferences
Aug 7 · 15:02 MT Newswires
Wedbush Adjusts PT on Solid Biosciences to $15 From $16, Maintains Outperform Rating
Aug 6 · 20:08 PR GlobeNewswire
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Overview

52-week range
$3.79
$11
84% of range
Avg surprise (last 3)
-7.9%
Avg reaction (last 2)
+1.0%
100% positive
Latest IV / EM
78%
EM ±12.2% · $10 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.54$-1.25$-0.96$-0.67$-0.38 Actual $-1.54Actual $-1.25Actual $-1.05Actual $-0.64Actual $-0.61Actual $-0.79Actual $-0.59Est $-0.53Actual $-0.42Est $-0.51Actual $-0.48Actual $-0.52Est $-0.40Actual $-0.38 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-57M$-51M$-46M$-40M$-34M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.38 — — — — financials
Tue May 12, 2026Mar/2026 $-0.52 $-0.40 -30.0% +11.9% +0.5% earnings
Tue Sep 30, 2025Sep 2025 $-0.48 — — — — financials
Tue Aug 12, 2025Jun/2025 $-0.42 $-0.51 +17.6% — — earnings
Thu May 15, 2025Mar/2025 $-0.59 $-0.53 -11.3% — +1.6% earnings
Mon Sep 30, 2024Sep 2024 $-0.79 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.61 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.64 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.05 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.25 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.54 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-57M$-57M—$-48M$-42M$-40M—$-35M
Net income$-55M$-57M—$-46M$-39M$-39M—$-33M
EPS (diluted)$-0.38$-0.52—$-0.48$-0.42$-0.59—$-0.79

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$159M$297M$60M$61M$139M$211M$80M$64M
Inventory————————
Total current assets$395M$397M$205M$245M$279M$313M$157M$179M
Total assets$421M$423M$233M$274M$308M$344M$189M$212M
Long-term debt————————
Total liabilities$47M$49M$53M$56M$50M$49M$51M$45M
Total equity$374M$374M$180M$218M$258M$294M$137M$167M

Implied volatility — last 90 days

45%194%343%491%640% Jun 08 — IV 437% · EM ±57.7%Jun 09 — IV 167% · EM ±20.9%Jun 10 — IV 640% · EM ±75.6%Jun 11 — IV 150% · EM ±16.6%Jun 12 — IV 85% · EM ±8.7%Jun 15 — IV 291% · EM ±21.1%Jun 16 — IV 623% · EM ±36.8%Jun 17 — IV 161% · EM ±6.7%Jun 19 — IV 92% · EM ±20.4%Jun 22 — IV 92% · EM ±19.3%Jun 23 — IV 75% · EM ±15.4%Jun 24 — IV 82% · EM ±16.4%Jun 25 — IV 104% · EM ±20.3%Jun 26 — IV 89% · EM ±17.0%Jun 30 — IV 171% · EM ±29.5%Jul 01 — IV 299% · EM ±50.0%Jul 02 — IV 115% · EM ±18.7%Jul 03 — IV 120% · EM ±18.7%Jul 06 — IV 72% · EM ±9.9%Jul 15 — IV 290% · EM ±17.2%Jul 16 — IV 265% · EM ±11.1%Jul 20 — IV 48% · EM ±11.2%Jul 21 — IV 93% · EM ±21.6%Jul 22 — IV 78% · EM ±17.9%Jul 23 — IV 104% · EM ±23.5%Jul 24 — IV 118% · EM ±26.2%Jul 27 — IV 129% · EM ±26.9%Jul 28 — IV 313% · EM ±64.0%Jul 29 — IV 206% · EM ±41.2%Jul 30 — IV 90% · EM ±17.7%Jul 31 — IV 97% · EM ±18.6%Aug 03 — IV 116% · EM ±20.6%Aug 04 — IV 344% · EM ±59.2%Aug 06 — IV 107% · EM ±17.3%Aug 07 — IV 46% · EM ±7.2%Aug 10 — IV 148% · EM ±20.4%Aug 12 — IV 110% · EM ±13.8%Aug 13 — IV 84% · EM ±9.9%Aug 24 — IV 118% · EM ±24.6%Aug 25 — IV 154% · EM ±31.6%Aug 26 — IV 116% · EM ±23.1%Aug 27 — IV 73% · EM ±14.3%Aug 28 — IV 84% · EM ±16.1%Aug 31 — IV 78% · EM ±13.8%Sep 02 — IV 67% · EM ±11.2%Sep 03 — IV 76% · EM ±12.2%Sep 04 — IV 78% · EM ±12.2%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in